Aker BioMarine

Share Issue/Capital Change • May 6, 2024

Aker BioMarine ASA – Offer under Employee Share Purchase Program and share capital increase

Aker BioMarine ASA – Offer under Employee Share Purchase Program and share capital increase

6 May 2024: Aker BioMarine ASA (the "Company") has renewed its offer of new shares to employees in the Company and its Norwegian subsidiaries on similar terms as for 2023 (the "Employee Share Purchase Program"). The deadline for acceptance of the offer in the Employee Share Purchase Program expired on 3 May 2024, at 16:30 CET.

The offer price for the shares in the Employee Share Purchase Program has been set to approximately NOK 56,72 (the "Offer Price"). The Offer Price is based on the volume-weighted average share price for the Company's shares on the Oslo Stock Exchange during the last five trading days prior to, and including, the last day of the application period, with a discount of 20%. Any shares acquired in the Employee Share Purchase Program will be subject to a lock-up period of two years, and the reduced offer price shall reflect the value-reducing effect of the lock-up period.

Based on the applications received in the Employee Share Purchase Program, the board of directors of the Company has allocated a total of 12 266 new shares to the participants in the Employee Share Purchase Program (the "Program Shares").

Furthermore, the board of directors has, on the basis of the authorisation granted to it by the annual general meeting held on 16 April 2024, resolved to increase the share capital of the Company with NOK 73 596, by issuance of 12,266 new shares, each with a nominal value of NOK 6.00, at a subscription price equal to the Offer Price. The Program Shares comprise approximately 0.01% of the existing and outstanding shares in the Company prior to their issuance.

Following the registration of the share capital increase with the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret), the new share capital of the Company will be NOK 526 110 084, divided into 87 685 014 shares, each with a nominal value of NOK 6.00.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

For further information, please contact

Katrine Klaveness, CFO

Mobile: +47 991 58 915

Email: Katrine.Klaveness@akerbiomarine.com

About Aker BioMarine

Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company developing krill-

derived products for pharma, consumer health and wellness as well as animal nutrition. The

company has a strong position in its industry and is the world's leading supplier of krill, the natural,

powerful and health promoting source of nutrients from the pristine waters of Antarctica. Aker

BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available at

www.akerbiomarine.com.